No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CLX240712C135000
- 0.45
- -0.14-23.73%
15min DelayClose Jul 11 16:00 ET
1.15High0.33Low
0.80Open0.59Pre Close29 Volume43 Open Interest135.00Strike Price1.39KTurnover18.37%IV0.45%PremiumJul 12, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.45Extrinsic Value100Contract SizeAmericanOptions Type0.4613Delta0.2926Gamma283.87Leverage Ratio-0.3820Theta0.0019Rho130.94Eff Leverage0.0293Vega
Intraday
- 5D
- Daily
News
Clorox Announces Aug. 1 Webcast of Fourth-Quarter and Fiscal Year 2024 Results
The Clorox Company (NYSE: CLX) will issue its fourth-quarter and fiscal year 2024 results on Aug. 1, 2024. Timing for the announcement will be as...
The Clorox Company (NYSE:CLX) Is a Favorite Amongst Institutional Investors Who Own 81%
Clorox Is Maintained at Neutral by Citigroup
Clorox Is Maintained at Neutral by
Express News | Citigroup Maintains Neutral on Clorox, Lowers Price Target to $145
Clorox Is Maintained at Underweight by Wells Fargo
Clorox Is Maintained at Underweight by Wells
Clorox Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 -1.4% Wells Fargo $135 → $130 Maintains Underweight 06/24/2024 -1.4% Exane BNP Paribas → $130
Comments
Investors seem more bullish on Clorox than analysts, as indicated by its high P/S ratio. However, its high share price may not be justified by forecasted revenues, posing risks for shareholders and potential investors.
1
Clorox's accrual ratio and unusual items hint at conservative statutory earnings. Its underlying earnings potential is likely higher. Analysts are optimistic about its future profitability.
Deutsche Bank analyst Steve Powers raised his price target to $156 from $140 and maintained a Neutral rating. Barclays analyst Lauren Liberman expects 2024 earnings of $6.21 a share, 13% higher than the company's estimates, and raised her price target to $148 from $118 while maintaining an Underweight rating. BofA Securities analyst Anna Lizzul also raised her price target, to $160 from $150, while maintaining a Neutral rating.
1
The company's recovery from last year's cybersecurity attack is reflected in strong Q2 results. The updated full-year outlook shows confidence in H2 performance, despite unfavorable foreign-exchange rates.
Read more